Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study.

ABSTRACT:

Objectives

To determine whether a polymorphism in the Fcγ receptor type IIIA (FCGR3A-F158V), influencing immunoglobulin G binding affinity, relates to the therapeutic efficacy of rituximab in rheumatoid arthritis (RA) patients.

Design

Observational cohort study.

Setting

Three university hospital rheumatology units in Sweden.

Participants

Patients with established RA (n=177; 145 females and 32 males) who started rituximab (Mabthera) as part of routine care.

Primary outcome measures

Response to rituximab therapy in relation to FCGR3A genotype, including stratification for sex.

Results

The frequency of responders differed significantly across FCGR3A genotypes (p=0.017 in a 3×2 contingency table). Heterozygous patients showed the highest response rate

SUBMITTER: Kastbom A 

PROVIDER: S-EPMC3467642 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature